Literature DB >> 2816810

Type II estrogen receptors in the papillary cystic tumor of the pancreas.

A Carbone1, F O Ranelletti, A Rinelli, F M Vecchio, L Lauriola, M Piantelli, A Capelli.   

Abstract

Two cases of papillary cystic tumor (PCT) of the pancreas were investigated for the presence of estrogen receptors (ERs) and progesterone receptors (PgRs). Both PCT and normal pancreas are able to specifically bind 3H-estradiol. This binding almost exclusively results from the presence of high levels of type II ER, whereas type I ERs were absent or present at very low levels. Both normal and neoplastic pancreas studied immunohistochemically for the presence of nuclear ER had negative results. This could be explained assuming that anti-ER antibodies are specific for type I binding sites. In conclusion, the presence of specific estrogen as well as progesterone binding may explain the sex and age predilection of PCT and suggest a possible hormone sensitivity for this tumor.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2816810     DOI: 10.1093/ajcp/92.5.572

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  11 in total

1.  Type II oestrogen binding sites in human colorectal carcinoma.

Authors:  M Piantelli; R Ricci; L M Larocca; A Rinelli; A Capelli; S Rizzo; G Scambia; F O Ranelletti
Journal:  J Clin Pathol       Date:  1990-12       Impact factor: 3.411

2.  Characterisation of oestrogen receptor, progesterone receptor, trefoil factor 1, and epidermal growth factor and its receptor in pancreatic cystic neoplasms and pancreatic ductal adenocarcinoma.

Authors:  T-S Yeh; Y-Y Jan; C-T Chiu; Y-B Ho; T-C Chen; K-F Lee; K-M Chan; J-C Hsu; T-L Hwang; M-F Chen
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

3.  Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells.

Authors:  Barry M Markaverich; Mary Vijjeswarapu; Kevin Shoulars; Mary Rodriguez
Journal:  J Steroid Biochem Mol Biol       Date:  2010-06-15       Impact factor: 4.292

4.  Expression of progesterone receptors in solid-cystic tumour of the pancreas: a clinicopathological and immunohistochemical study of ten cases.

Authors:  G Zamboni; F Bonetti; A Scarpa; G Pelosi; C Doglioni; A Iannucci; P Castelli; G Balercia; D Aldovini; A Bellomi
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

5.  Regulation of cell cycle and RNA transcription genes identified by microarray analysis of PC-3 human prostate cancer cells treated with luteolin.

Authors:  Kevin Shoulars; Mary Ann Rodriguez; Trellis Thompson; Barry M Markaverich
Journal:  J Steroid Biochem Mol Biol       Date:  2009-10-27       Impact factor: 4.292

6.  Papillary-cystic neoplasm of the pancreas. A sex-steroid dependent tumor.

Authors:  A Morales; J M Ruíz Molina; H O Estéves; G Robles-Díaz; V Díaz-Sánchez
Journal:  Int J Pancreatol       Date:  1998-12

7.  Quercetin inhibits the growth of a multidrug-resistant estrogen-receptor-negative MCF-7 human breast-cancer cell line expressing type II estrogen-binding sites.

Authors:  G Scambia; F O Ranelletti; P Benedetti Panici; M Piantelli; G Bonanno; R De Vincenzo; G Ferrandina; L Pierelli; A Capelli; S Mancuso
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

8.  Multiple Sites of Type II Site Ligand (Luteolin and BMHPC) Regulation of Gene Expression in PC-3 Cells.

Authors:  Barry M Markaverich; Mary Vijjeswarapu
Journal:  Int J Biomed Sci       Date:  2012-12

9.  Effects of coumestrol on estrogen receptor function and uterine growth in ovariectomized rats.

Authors:  B M Markaverich; B Webb; C L Densmore; R R Gregory
Journal:  Environ Health Perspect       Date:  1995-06       Impact factor: 9.031

10.  Expression of estrogen receptors during growth of human pancreatic adenocarcinoma cells (Capan-1)-relationship with differentiation.

Authors:  E Hollande; M Fanjul; N Houti; J C Faye; P Courriere
Journal:  In Vitro Cell Dev Biol Anim       Date:  1998 Jul-Aug       Impact factor: 2.723

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.